January 2022 – UGGC Avocats, a multidisciplinary business law firm, advised AdBio Partners, formerly Advent France Biotechnology, one of the leading investment funds in the life sciences industry, on the acquisition of the French biotech company SynHelix, a company specialized in DNA synthesis technology, by the Belgian group Univercells, which specializes in the manufacture and marketing of equipment for the production of vaccines and biotreatments. SynHelix will become “Quantoom Research Center” to complement Univercells’ offer.
SynHelix will optimize the RNA platform developed by Quantoom Biosciences SA (Quantoom), the Univercells subsidiary that develops end-to-end RNA production technology and associated vaccine production. Through this acquisition, the group wishes to democratize messenger RNA technology at a European level.
Univercells had already reorganized itself into four distinct business lines to clarify its entrepreneurial missions. This fifth branch will boost the group’s development and strengthen its European network.
The UGGC Avocats team that assisted AdBio Partners in this transaction was composed of :
– Charles-Emmanuel Prieur (UGGC Avocats Paris – partner)
– Jean-Nicolas Goossens (UGGC Avocats Brussels – partner)
– Rebecca El Hakim (UGGC Avocats Paris – associate)
Other advisors involved in the transaction :
Freshfields Bruckhaus Deringer LLP (Paris and Brussels offices)
About UGGC Avocats
Founded in 1993, UGGC Avocats is one of the leading independent business law firms in France. UGGC Avocats assists private and public operators. The firm has extensive expertise in legal and tax matters; through its teams and its “family office”, it offers a very large capacity of intervention in France and internationally (Europe, Africa, Asia and South America). UGGC Avocats is positioned as a “client firm” and its approach is based on its ability to mobilize multidisciplinary teams adapted to its clients’ needs. UGGC Avocats gathers more than 150 lawyers, including 33 partners.